Best Life Sciences Companies in Utah, United States
The 274 best Life Sciences companies in Utah, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: NU Skin.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Utah
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | NU Skin Manufacturer of anti-aging products | $751M | 56 mo ago | 1,900 1,900 → 3,522 (+85%) · sector median +42% | 1984 | — | 33 patents Dermatology: skin treatment devices and antioxidant formulations for ROS reduction and photonic monitoring. | — |
| 2 | Ancestry Provider of an online genealogy platform offering a host of services | $446M | 122 mo ago | 1,228 1,228 → 1,863 (+52%) · sector median +42% | 1996 | — | — | 1 partnership |
| 3 | Sera Prognostics Developer of biomarker-based tests for pregnancy care | $258M | 62 mo ago | 123 123 → 80 (-35%) · sector median +42% | 2008 | Gregory Critchfield CEO | 127 patents Predictive protein/biomarker assays for pregnancy timing and complications | — |
| 4 | Varex Developer of imaging equipment and accessories | $175M | 72 mo ago | 2,400 | 2017 | — | — | — |
| 5 | MasterControl 🦄 Developer of software for quality, manufacturing, and asset management solutions | $150M | 42 mo ago | 560 | 1994 | — | 19 patents Enterprise software compliance automation and AI-driven knowledge graph/text analytics solutions. | — |
| 6 | NuView Life Sciences Developer of device for the diagnosis of cancer | $90M | 70 mo ago | 6 | 2005 | Paul Crowe CEO | — | — |
| 7 | biofire diagnostics BioFire Diagnostics is a biotech company that detects pathogens and mutations for molecular diagnostics. | $84M | 43 mo ago | 848 | 1990 | — | 227 patents Integrated rapid cell lysis and nucleic‑acid extraction for point‑of‑care infectious diagnostics | — |
| 8 | DiscGenics Developer of tissue engineering technology to treat patients debilitated by degenerative disc disease | $71M | 69 mo ago | 45 45 → 41 (-9%) · sector median +42% | 2008 | Flagg Flanagan Chief Executive Officer & Chairman of the Board | 89 patents Regenerative intervertebral disc cell therapies, isolation, cryopreservation, and delivery devices. | 1 launch |
| 9 | Lineagen Sequencing-based diagnostic test and consultative services for autism | $67M | 136 mo ago | 40 | 2002 | — | 85 patents Genetic biomarkers and diagnostic tests for autism, developmental delays, and seizure disorders | — |
| 10 | Clene Nanomedicine Developer of therapeutics for the treatment of neurodegenerative diseases 29Funding top 29%Patents top 36%Tech top 41%Innovation top 47% All 10 signals ▾Fundingtop 29% Patentstop 36% Techtop 41% Innovationtop 47% Growthbottom 49% Moatbottom 44% Globalbottom 42% Marketbottom 32% Newsbottom 32% Fin. healthbottom 15% Funding: Raised $59.1M across 8 rounds · 8 rounds over 7 yrs (1.1/yr) Patents: 78 patents matched (strict assignee match) · 10 filings since 2022 vs 60 in 2017-21 rank vs industry peers · Fliar Intelligence Index 29/100 | $59M | 20 mo ago | 99 | 2012 | — | 78 patents Continuous nanomaterial synthesis and gold nanocrystal production for neuroregenerative therapies | — |
| 11 | Owlet Provider of wearable socks for baby monitoring | $51M | 40 mo ago | 211 211 → 354 (+68%) · sector median +42% | 2013 | Zack Bomsta Co-Founder | — | — |
| 12 | Carterra Developer of a SPR based platforms to study enzyme kinetics | $45M | 30 mo ago | 84 | 2004 | Christian Giddens Director Of Sales | 15 patents High-throughput microfluidic scanning and biomolecular interaction analysis platforms | — |
| 13 | Foldax Developer of bio-polymeric heart valves to treat aortic, mitral, and tricuspid valve diseases | $44M | 32 mo ago | 46 | 2006 | Mory Gharib Co-Founder | 82 patents Manufacturing, material design, and delivery systems for implantable prosthetic heart valves | 1 job opening · 1 launch |
| 14 | PolarityTE Developer of regenerative medicine | $42M | 24 mo ago | 37 | 1998 | — | 63 patents Patents concentrated in chemistry & materials | — |
| 15 | Elevar Therapeutics Developer of therapeutic agents for treating cancer | $40M | 85 mo ago | 87 | 2005 | Alex Kim CEO | — | — |
| 16 | Lipocine Develops oral versions of hormones using Hydroance drug delivery technology | $38M | 154 mo ago | 17 17 → 24 (+41%) · sector median +42% | 1997 | — | 366 patents Oral steroid formulations for hormonal, CNS, and liver disease therapies | 1 launch |
| 17 | Techcyte Artificial intelligence (AI) based image analysis platform for pathologists 72AI top 22%Funding top 30%Product top 30%Patents top 32% All 11 signals ▾AItop 22% Fundingtop 30% Producttop 30% Patentstop 32% Moattop 32% Innovationtop 33% Growthtop 35% Newstop 39% Techtop 48% Marketbottom 47% Globalbottom 40% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Funding: Raised $35.4M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 72/100 | $35M | 1 mo ago | 100 | 2014 | — | 34 patents Automated image analysis for microscopy and agglutination-based diagnostic assays. | 1 partnership |
| 18 | Navigen Pharmaceuticals Peptide and small molecule therapeutics for infectious diseases | $34M | 84 mo ago | 22 | 2007 | — | — | — |
| 19 | Biofire Defense Biological agent identification products and services for biodefense and first responders | $34M | 142 mo ago | 150 | 1990 | Randy Rasmussen Co-Founder & CEO | 191 patents Rapid on-site nucleic acid testing and fast PCR molecular diagnostics solutions. | 2 launchs · 1 partnership |
| 20 | Techniscan Medical Systems Innovating medical imaging with advanced breast ultrasound technology | $31M | 186 mo ago | — | 1986 | David Borup Founder | — | — |
| 21 | Halia Provider of chronic inflammation therapy | $30M | 11 mo ago | 18 | 2017 | Jared Bearss Co-Founder | — | — |
| 22 | Capstone Nutrition Contract manufacturer of nutrition, supplements, personal care, and pet care products | $30M | 104 mo ago | 381 381 → 275 (-28%) · sector median +42% | 1992 | — | — | — |
| 23 | PhotoPharmics Developer of non-invasive phototherapy for Parkinson's disease 42Funding top 29%Moat top 32%Growth top 35%Product top 40% All 9 signals ▾Fundingtop 29% Moattop 32% Growthtop 35% Producttop 40% Techtop 42% Patentstop 42% Innovationtop 44% Globalbottom 35% Marketbottom 21% Funding: Raised $29.7M across 11 rounds · 11 rounds over 14 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 31 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $30M | 13 mo ago | 7 | 2011 | — | 31 patents Photonic light‑emitting devices for neuro‑ophthalmic diagnosis and therapy | — |
| 24 | IDbyDNA Developer of search engine to identify pathogens in sample | $29M | 76 mo ago | 75 | 2014 | — | 27 patents Targeted metagenomic sequencing and microbial identification for antimicrobial resistance profiling | — |
| 25 | Zarbees Developer of natural cough remedies and other natural health and wellness products | $28M | 141 mo ago | 32 | 2008 | — | 19 patents Pharmaceutical packaging and oral dosage forms, especially gummy products and dispensing bottle caps | — |
| 26 | Great Basin Scientific Sample-to-Result molecular diagnostics devices company | $28M | 119 mo ago | 182 | 2005 | — | — | — |
| 27 | Second Heart A minimally invasive circulatory support platform | $24M | 53 mo ago | 5 | 2015 | Howard Leonhardt Co-Founder | 25 patents Implantable ventricular assist pumps and wireless power‑transfer circulatory support systems. | — |
| 28 | Blackrock Neurotech Developer of medical devices for neurological therapies | $22M | 13 mo ago | 127 127 → 191 (+50%) · sector median +42% | 2008 | Florian Solzbacher Co-Founder & CSO | — | — |
| 29 | Kiora Pharmaceuticals Developer of therapies for the treatment of different types of eye diseases | $20M | 2 mo ago | 12 12 → 17 (+42%) · sector median +42% | 2013 | Brian Strem CEO | — | 1 launch |
| 30 | MARAbio Developer of blood test for detecting maternal autoantibody-related autism | $19M | 21 mo ago | 4 | 2016 | Judy Water Co-Founder | — | — |
| 31 | Boka Sciences Provider of saliva-based real time health monitoring devices | $18M | 72 mo ago | 5 | 2008 | Porter Jones CEO | — | — |
| 32 | CoNextions Medical Implant for the repair of tendons | $14M | 64 mo ago | 13 13 → 9 (-31%) · sector median +42% | 2011 | — | — | — |
| 33 | Seek Labs Developer of a technology for the treatment and diagnostics of infectious diseases. 53AI top 15%Patents top 27%Innovation top 28%Moat top 32% All 9 signals ▾AItop 15% Patentstop 27% Innovationtop 28% Moattop 32% Fundingtop 33% Talentbottom 49% Techbottom 44% Globalbottom 31% Marketbottom 29% AI: Holds AI/ML patents (G06N-family CPC) Patents: 48 patents matched (strict assignee match) · 30 filings since 2022 vs 12 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $14M | 4 mo ago | 27 | 2017 | Jared Bauer CEO | 48 patents Molecular diagnostics and CRISPR-based nucleic acid testing for veterinary disease detection | — |
| 34 | Epitel Provider of a wearable EEG recording system for epilepsy monitoring and control 53Moat top 25%Innovation top 27%Patents top 28%Funding top 34% All 10 signals ▾Moattop 25% Innovationtop 27% Patentstop 28% Fundingtop 34% Growthtop 35% Talentbottom 49% Techbottom 47% Globalbottom 40% Marketbottom 32% Newsbottom 18% Moat: Editorial + unicorn rating 7/10 · IP moat: 56 patents Innovation: 56 patents (top 28% of patent-holders) · 47 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $12M | 10 mo ago | 39 | 2007 | Mark Lehmkuhle Founder & CEO | 56 patents AI-driven EEG monitoring devices for seizure detection and neurodiagnostic analytics | 1 launch · 1 award |
| 35 | Fluidx Medical Technology Developer of an embolic device to control vascular occlusion | $12M | 26 mo ago | 6 | 2015 | Lawrence Kronick Co-Founder | — | 3 launchs · 1 award |
| 36 | Quadrant Biosciences Technologies for the evaluation of brain health and autism spectrum disorders | $12M | 34 mo ago | 101 | 2015 | Richard Uhlig Chief Executive Officer | 39 patents AI-driven molecular diagnostics and biomarker profiling for neurological and metabolic disorders | — |
| 37 | Xenocor Provider of Laparoscopic imaging system for surgeries | $10M | 38 mo ago | 11 | 2000 | Ashok Khandkar CEO | 32 patents Patents concentrated in computing, sensing & instrumentation | — |
| 38 | Inherent Biosciences Developer of epigenetic diagnostics and therapeutics for complex diseases | $9M | 14 mo ago | 15 | 2019 | Kristin Brogaard Co-Founder & CSO | — | — |
| 39 | Thunder Biotech Developer of genetically engineered macrophage immunotherapy for solid tumors. | $8M | 28 mo ago | 24 | 2016 | Kim Neill Founder | — | — |
| 40 | Rebel Medicine Developer of therapeutics for pain management | $7M | 16 mo ago | 9 | 2018 | — | 18 patents Analgesic drug formulations, especially oil‑in‑water emulsions for pain relief | — |
| 41 | Echelon Biosciences Lipid and cell signaling solutions for diagnostics and drug treatments | $7M | 20 mo ago | 20 | 1997 | Jeremy Amberson President and CEO | — | 3 launchs |
| 42 | Curza Developing novel antibiotics to combat antibiotic resistance and infectious diseases | $6M | 13 mo ago | 15 | 2007 | — | 70 patents Novel antimicrobial agents for crop protection and human therapeutics. | — |
| 43 | Co-Dx Provider of genomics-based information and solutions for transplant patients | $4M | 35 mo ago | 155 | 2013 | Dwight Egan CEO | — | — |
| 44 | Control Medical Technology Innovative thrombectomy solutions improving patient outcomes through advanced medical device technology | $4M | 23 mo ago | 8 | 2008 | — | — | — |
| 45 | 3Helix Developer of reagents that specifically bind denatured collagen | $4M | 31 mo ago | 8 | 2015 | Yang Li Founder & CEO | 26 patents Collagen‑targeted therapeutic peptides and fibrosis detection diagnostics | — |
| 46 | iVeena Delivery Systems Ophthalmology company developing disease-modifying eye drops for keratoconus and myopia | $3M | 16 mo ago | 6 | 2012 | — | — | — |
| 47 | ReddyPort Innovative oral care and communication solutions for non-invasive ventilation (NIV) patients | $3M | 8 mo ago | 6 | 2015 | Tony Lair CEO | 10 patents Advanced positive‑pressure ventilation devices and integrated monitoring accessories for respiratory care | — |
| 48 | Purgo Scientific Developer of drug delivery device to combat surgical site infections | $2M | 31 mo ago | — | 2017 | Mike Benjamin Chief Executive Officer | — | — |
| 49 | Sethera Therapeutics Provider of peptide-based drug discovery platform | $2M | 20 mo ago | — | 2024 | Alyson Lord Co-Founder | — | — |
| 50 | SphenoCath Precision intra-nasal medicine delivery device improving patient outcomes | $800K | 21 mo ago | — | 2010 | — | — | — |
Top 12 Life Sciences companies in Utah
#1
Series B · Orem, Utah · founded 2014 · 100 employees$35.4Mraised▾
Artificial intelligence (AI) based image analysis platform for pathologists. The tool called Techcyte uses several Artificial intelligence (AI) platforms to perform image analysis on digital microscopy images. Also developing AI-based digital analysis tools for hematology tests, cervical cytology tests, ova and parasites (O&P) fecal tests for humans as well as animal samples. The company has collaborated with Motic, a leading provider of whole slide scanners to provide advanced solutions for scanning, image analysis, workflow, and reporting recently.
- Apr 2026Series B$15M
- Dec 2023Series B$8.4M
- Aug 2021Series B$21M
- Jan 2018Series A$4.3M
#2
Public · Salt Lake City, Utah · founded 2013 · 12 employees$20.2Mraised▾
Developer of therapies for the treatment of different types of eye diseases. The company lead product candidate KIO-301 is a molecular photoswitch that has the potential to restore light perception in patients with inherited and age-related retinal degeneration. Other drug candidates include KIO-101 for Dry Eye Disease, KIO-201 for PRK surgical recovery, and KIO-102 (Oral) for autoimmune diseases.
- Apr 2026Post IPO$5M
- Jan 2024Post IPO$15M
- Feb 2023Post IPO$200K
#3
Series B · Salt Lake City, Utah · founded 2017 · 27 employees$13.6Mraised▾
Developer of a technology for the treatment and diagnostics of infectious diseases. It offers point-of-care diagnostic and clustered regularly interspaced short palindromic repeats (CRISPR)-based technologies to detect and treat infectious diseases.
- Feb 2026Grant (prize money)$2M
- Aug 2023Series B$13.6M
#4
Series C · Lehi, Utah · founded 2017 · 18 employees$30Mraised▾
Provider of chronic inflammation therapy. It offers APOE4 carriers that avoid Alzheimers due to protective mutations, HT-6184 enhances semaglutide efficacy while preserving lean mass for obesity, and resilience variants show immune system restoration via NEK7 inhibition for MDS.
- Jul 2025Series C$336.8K
- Jan 2024Series C$30M
#5
Series A · Salt Lake City, Utah · founded 2007 · 39 employees$12.5Mraised▾
Provider of a wearable EEG recording system for epilepsy monitoring and control. It offers a scalp wearable medical-grade seizure monitoring system. The rechargeable device can be applied to the scalp by an adhesive and can be worn irrespective of time and location. The device is paired via Bluetooth with a mobile application that detects and records seizures. The obtained data can be then used by a doctor to optimize one's treatment and lifestyle.
- Aug 2025Grant (prize money)$6.3M
- Apr 2025Grant (prize money)$3.4M
- Feb 2022Series A$12.5M
- Dec 2019Seed—
#6
Series B · American Fork, Utah · founded 2011 · 7 employees$29.7Mraised▾
PhotoPharmics is a developer of non-invasive phototherapy for Parkinson's disease. Its previous investigations with light therapy and Parkinson’s disease have shown improvement in Parkinson’s symptoms. The therapy is designed to be used as an adjunct to drug treatment for Parkinson's disease. It is currently conducting a pivotal investigation at three sites in Amsterdam, Boston, and Salt Lake City to demonstrate the safety and efficacy of specialized phototherapy for Parkinson’s disease.
- Apr 2025Series B$6M
- Sep 2024Grant (prize money)$319.3K
- Oct 2023Series B$26.2M
- Jun 2021Grant (prize money)$320K
#7
Acquired · Salt Lake City, Utah · founded 2008 · 127 employees$22.4Mraised▾
Developer of medical devices for neurological therapies
- May 2025Grant (prize money)$969.7K
- Mar 2025Grant (prize money)$969.7K
- Apr 2024Series B$12.4M
- Sep 2023Grant (prize money)$1.5M
#8
Public · Salt Lake City, Utah · founded 2012 · 99 employees$59.1Mraised▾
Developer of therapeutics for the treatment of neurodegenerative diseases. The company focused on revolutionizing the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Their approach centers on developing novel clean-surfaced nanotechnology therapeutics that target cellular energy impairments common in these diseases to restore and protect neuronal health and function.
- Oct 2024Post IPO$7.3M
- Dec 2021Grant (prize money)$1M
- May 2021Post IPO$9.2M
- Aug 2020Series D$42.5M
#9
Series A · Salt Lake City, Utah · founded 2015 · 6 employees$2.9Mraised▾
Innovative oral care and communication solutions for non-invasive ventilation (NIV) patients. They provide solutions that enable oral access for moisture relief and oral care for BiPAP patients without mask removal. Their system allows clinicians to provide dry mouth relief, routine oral care, and effective communication without BiPAP mask removal. This easy-to-use tool can be used by caregivers, patients, or family members to deliver compliant oral care. They focus on NV-HAP mitigation, offering resources and education to improve patient outcomes and reduce hospital-acquired pneumonia risks. Their products support better workflows and enhance the quality of care for NIV patients. They offer NIV Oral Care Kits, components, and a microphone.
- Oct 2025Series A$251.9K
- Nov 2023Series A$2.5M
- Jun 2018Seed$400K
#10
Series A · Salt Lake City, Utah · founded 2019 · 15 employees$9.1Mraised▾
Developer of epigenetic diagnostics and therapeutics for complex diseases. It focuses on identifying dysregulation across multiple genes and related pathways. It aims to transform the diagnosis and treatment of complex diseases like infertility through its epigenetic platform. The company's initial product, SpermQT, seeks to improve fertility testing and provide personalized treatment plans.
- Apr 2025Grant (prize money)$1.9M
- Feb 2025Grant (prize money)$1.9M
- Jan 2025Grant (prize money)$1.9M
- Feb 2024Grant (prize money)$1M
#11
Series A · Salt Lake City, Utah · founded 2007 · 15 employees$5.6Mraised▾
Developing novel antibiotics to combat antibiotic resistance and infectious diseases. This is a small-molecule therapeutics company focused on infectious diseases, developing structurally distinct classes of proprietary drugs. The company aims to combat the rising epidemic of antibiotic resistance by developing novel antibiotic classes. Their lead program targets drug-resistant Gram-negative bacteria, specifically ESKAPE pathogens, using an unexploited binding site of the bacterial ribosome. They are also developing novel antibiotics for ESKAPE pathogens or "superbugs" and antibiofilm antibiotics to treat biofilm-related infections. This is a B2B tech company focused on pharmaceutical research and development.
- Apr 2025Grant (prize money)$2M
- Apr 2025Grant (prize money)$2M
- Jul 2024Grant (prize money)$1M
- May 2024Grant (prize money)$1000K
#12
Series A · Salt Lake City, Utah · founded 2018 · 9 employees$7.2Mraised▾
Developer of therapeutics for pain management. It offers Alevatrx injectable local anesthetic formulation for postoperative pain and Alevaderm is a local anesthetic wound dressing for painful dermal injuries.
- Feb 2025Series A$6.1M
- Jan 2025Grant (prize money)$295.9K
- Sep 2024Grant (prize money)$295.9K
- Sep 2021Grant (prize money)$263.1K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Utah is moving
A read on the academic research around Biotechnology in Utah — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 40 papers.
Utah's University of Utah and Utah State University optimistically advance CRISPR, cancer genetics, and biomedical 3D printing research, with recent output doubling earlier work amid minimal concern.
- University of Utah29
- Utah State University5
- Mutah University4
- University of Utah Health Care2
- Utah AIDS Foundation1
- RNA interference3
- RNA silencing2
- Flow cytometry2
- Fluorescence2
- Biosensor2
- Cell biology2
- Computational biology2
- Agriculture2
- Type I collagen2
- Mitochondrion1
- Recombination1
- Centromere1
- Breakpoint1
- Segmental duplication1
- Allele1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.